Oncocyte [OCX] vs Danaher [DHR] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Oncocyte Corporation wins in 6 metrics, Danaher Corporation wins in 11 metrics, with 0 ties. Danaher Corporation appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Oncocyte Corporation | Danaher Corporation | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.81 | 34.61 | Danaher Corporation |
| Price-to-Book Ratio | 109.66 | 2.40 | Danaher Corporation |
| Debt-to-Equity Ratio | 3.07 | 37.17 | Oncocyte Corporation |
| PEG Ratio | 0.05 | 3.84 | Oncocyte Corporation |
| EV/EBITDA | -2.86 | 17.69 | Danaher Corporation |
| Profit Margin (TTM) | 39.34% | 14.89% | Oncocyte Corporation |
| Operating Margin (TTM) | -3,220.57% | 22.94% | Danaher Corporation |
| EBITDA Margin (TTM) | N/A | 22.94% | N/A |
| Return on Equity | 496.38% | 7.08% | Oncocyte Corporation |
| Return on Assets (TTM) | -173.67% | 4.19% | Danaher Corporation |
| Free Cash Flow (TTM) | $-21.23M | $5.26B | Danaher Corporation |
| Dividend Yield | N/A | 0.56% | N/A |
| 1-Year Return | 87.05% | -3.81% | Oncocyte Corporation |
| Price-to-Sales Ratio (TTM) | 34.89 | 5.10 | Danaher Corporation |
| Enterprise Value | $60.65M | $140.38B | Danaher Corporation |
| EV/Revenue Ratio | 32.24 | 5.67 | Danaher Corporation |
| Gross Profit Margin (TTM) | 67.57% | 60.34% | Oncocyte Corporation |
| Revenue per Share (TTM) | $0 | $35 | Danaher Corporation |
| Earnings per Share (Diluted) | $-4.66 | $5.16 | Danaher Corporation |
| Beta (Stock Volatility) | N/A | 0.99 | N/A |
| Short % of Float | N/A | 1.10% | N/A |
Oncocyte Corporation vs Danaher Corporation Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Oncocyte Corporation | 1.34% | -5.93% | 15.30% | 10.64% | 12.92% | -15.78% |
| Danaher Corporation | 1.12% | 2.86% | 2.32% | -12.71% | -22.05% | -22.71% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Oncocyte Corporation | 87.05% | 41.14% | -93.86% | -92.52% | -95.03% | -95.03% |
| Danaher Corporation | -3.81% | -12.18% | -14.95% | 176.52% | 423.71% | 744.91% |
Performance & Financial Health Analysis: Oncocyte Corporation vs Danaher Corporation
| Metric | OCX | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $65.62M | $126.39B |
| Market Cap Category | Micro cap | Large cap |
| 10 Day Avg. Volume | 363,828 | 5,174,666 |
| 90 Day Avg. Volume | 186,765 | 4,357,215 |
| Last Close | $6.03 | $178.08 |
| 52 Week Range | $2.33 - $8.51 | $160.93 - $242.80 |
| % from 52W High | -29.14% | -26.66% |
| All-Time High | $204.80 (Jan 04, 2016) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -97.06% | -39.85% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.76% | 0.04% |
| Quarterly Earnings Growth | N/A | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | 0.39% | 0.15% |
| Operating Margin (TTM) | -32.21% | 0.23% |
| Return on Equity (TTM) | 4.96% | 0.07% |
| Debt to Equity (MRQ) | 3.07 | 37.17 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.03 | $74.32 |
| Cash per Share (MRQ) | N/A | $8.06 |
| Operating Cash Flow (TTM) | $-63,291,000 | $6.44B |
| Levered Free Cash Flow (TTM) | $1.69M | $4.57B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.56% |
| Last 12-Month Dividend | N/A | $1.28 |
Valuation & Enterprise Metrics Analysis: Oncocyte Corporation vs Danaher Corporation
| Metric | OCX (Apr 08, 2026) | DHR (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.81 | 34.61 |
| Forward P/E | -1.85 | 19.64 |
| PEG Ratio | 0.05 | 3.84 |
| Price to Sales (TTM) | 34.89 | 5.10 |
| Price to Book (MRQ) | 109.66 | 2.40 |
| Market Capitalization | ||
| Market Capitalization | $65.62M | $126.39B |
| Enterprise Value | $60.65M | $140.38B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 32.24 | 5.67 |
| Enterprise to EBITDA | -2.86 | 17.69 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.99 |
| Book Value per Share (MRQ) | $0.03 | $74.32 |
Financial Statements Comparison: Oncocyte Corporation vs Danaher Corporation
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | OCX (2024) | DHR (2025) |
|---|---|---|
| Revenue/Sales | 1.88M | 24.57B |
| Cost of Goods Sold | 1.14M | 10.05B |
| COGS % of Revenue | 60.7% | 40.9% |
| Gross Profit | 740,000 | 14.52B |
| Gross Margin | 39.3% | 59.1% |
| Research & Development | 9.84M | 1.60B |
| Operating Income (EBIT) | -23.25M | 4.69B |
| Operating Margin | -1,235.9% | 19.1% |
| EBITDA | -21.22M | 7.17B |
| EBITDA Margin | -1,128.2% | 29.2% |
| Pre-Tax Income | -60.66M | 4.23B |
| Pre-Tax Income % of Revenue | -3,225.0% | 17.2% |
| Income Tax | N/A | 633.00M |
| Income Tax % of Revenue | 0.0% | 2.6% |
| Net Income (Profit) | -60.66M | 3.61B |
| Profit Margin | -3,225.0% | 14.7% |
Balance Sheet & Liquidity Metrics
| Metric | OCX (2024) | DHR (2025) |
|---|---|---|
| Cash & Equivalents | 8.64M | 4.62B |
| Total Current Assets | 11.76M | 12.76B |
| Total Current Assets % of Revenue | 625.1% | 51.9% |
| Total Current Liabilities | 7.28M | 6.81B |
| Total Current Liabilities % of Revenue | 386.8% | 27.7% |
| Long-Term Debt | 2.37M | 19.50B |
| Long-Term Debt % of Revenue | 125.9% | 79.4% |
| Total Shareholders Equity | -12.27M | 52.54B |
| Retained Earnings | -350.54M | 46.89B |
| Retained Earnings % of Revenue | -18,635.8% | 190.9% |
| Property, Plant & Equipment | 5.32M | 2.14B |
Cash Flow Statement Comparison
| Metric | OCX (2024) | DHR (2025) |
|---|---|---|
| Operating Cash Flow | -63.29M | 5.64B |
| Operating Cash Flow % of Revenue | -3,364.8% | 23.0% |
| Capital Expenditures | -512,000 | -1.12B |
| Free Cash Flow | -21.23M | 5.26B |
| FCF Margin | -1,128.6% | 21.4% |
| Debt Repayment | -201,000 | -500.00M |
| Common Stock Repurchase | -5.39M | -3.09B |
Short Interest & Institutional Ownership Analysis
| Metric | OCX | DHR |
|---|---|---|
| Shares Short | N/A | 6.94M |
| Short Ratio | N/A | 1.68 |
| Short % of Float | N/A | 1.10% |
| Shares Outstanding | 28.60M | 707.70M |
| Float Shares | N/A | 630.65M |
| % Held by Insiders | N/A | 10.78% |
| % Held by Institutions | N/A | 85.08% |
| % Held by Public | N/A | 4.14% |
Dividend Analysis & Yield Comparison: Oncocyte Corporation vs Danaher Corporation
| Metric | OCX | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.28 |
| Last 12-Month Dividend Yield | N/A | 0.56% |
| 3-Year Avg Annual Dividend | N/A | $10.51 |
| 3-Year Avg Dividend Yield | N/A | 1.11% |
| 3-Year Total Dividends | N/A | $31.54 |
| Ex-Dividend Date | N/A | Dec 26, 2025 |